Denali Therapeutics Inc

NASDAQ:DNLI

15.27

-0.38 (-2.43%)

6:02:19 PM EDT: $15.89 +0.62 (+4.06%)

Market Cap (Intraday)	2.18B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.36 Million
Adjusted EPS	-$0.75

See more estimates

10-Day MA	$15.23
50-Day MA	$14.43
200-Day MA	$17.43

See more pivots

Denali Therapeutics Inc Stock, NASDAQ:DNLI

161 Oyster Point Boulevard, 2nd Floor, San Francisco, California 94080

United States of America

Phone: +1.615.866.8548

Number of Employees: 422

http://www.denalitherapeutics.com

Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.